Abstract
Doxorubicin (Dox) is a potent and widely used anthracycline for cancer chemotherapy. However, the prevalence of Dox induced cardiotoxicity (DIC) in children and adolescents receiving Dox treatment is a major concern. While the exact molecular mechanisms of DIC remains to be fully elucidated, studies have reported cell death (apoptosis) as a major molecular mechanism in the occurrence of DIC. However, the presence of necroptosis in young DIC remains unknown. Therefore, in this study, we investigated the possible occurrence of necroptotic cell death in DIC in young mice in-vivo to delineate underlying pathological mechanism and the therapeutic ability of proprotein convertase substilisin/Kexin 9 inhibitors (PCSK9i) to attenuate doxorubicin induced necroptotic cell death and adverse cardiac remodeling. C57BL6 mice (6 + 2 weeks of age) were divided into three groups and administered the following treatments: Control (saline), Dox and Dox+PCSK9i. At D14 echocardiography was performed to examine heart function. Heart tissues were collected and analyzed for protein expression using immunohistochemistry and western blot to determine necroptosis and necroinflammation. Adverse cardiac remodeling was determined with histology stains for fibrosis and cardiac hypertrophy. Dox treatment significantly (p < 0.05) increased the expression of necroptotic markers [Receptor interacting Serine/Threonine kinase 1 and 3 (RIPK1, RIPK3) and Mixed Lineage kinase domain-Like (MLKL)], Necroinflammation markers [interleukin-33 (IL33) and interleukin-1α (IL-1α)], pro-inflammatory cytokines [interleukin- 6 (IL-6) and tumor necrosis factor alpha (TNF-α)], and induced adverse cardiac remodeling with significant increase (p < 0.05) in cardiac hypertrophy and fibrosis and significantly (p < 0.05) reduced cardiac function when compared to control. However, PCSK9i treatment showed a reduction in expression of necroptotic markers, necroinflammation markers and pro-inflammatory cytokines IL-6 and TNF-α, significant (p < 0.05) reductions in cardiac hypertrophy and fibrosis with improved heart function. Lastly, the result of our study shows that PCSK9i attenuates doxorubicin induced necroptosis and cardiac remodeling
Notes
If this is your thesis or dissertation, and want to learn how to access it or for more information about readership statistics, contact us at STARS@ucf.edu
Graduation Date
2022
Semester
Summer
Advisor
Singla, Dinender
Degree
Master of Science (M.S.)
College
College of Medicine
Department
Burnett School of Biomedical Sciences
Degree Program
Biotechnology
Identifier
CFE0009192; DP0026788
URL
https://purls.library.ucf.edu/go/DP0026788
Language
English
Release Date
8-15-2027
Length of Campus-only Access
5 years
Access Status
Masters Thesis (Campus-only Access)
STARS Citation
Imaralu, Omonzejie, "Effects of PCSK9i on Doxorubicin Induced Necroptosis" (2022). Electronic Theses and Dissertations, 2020-2023. 1221.
https://stars.library.ucf.edu/etd2020/1221
Restricted to the UCF community until 8-15-2027; it will then be open access.